Alzheimer’s drug that slows cognitive decline gets FDA approval
UCI MIND Director, Dr, Joshua Grill is quoted in the Washington Post about the meaningfulness of lecanemab’s clinical benefit. Further discussion on this topic is accessible on UCI MIND blog post.